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Abstract  
 Attention deficit hyperactivity disorder (ADHD) is a psychopathology commonly 
characterized by general inattentiveness and/or a lack of impulse control resulting in 
hyperactive tendencies. ADHD is estimated to cost the United States roughly $266 billion 
every year. ADHD is currently treated via medications, cognitive behavioral therapy, or 
more recently, neurofeedback. Neurofeedback – and biofeedback in general – is the 
process of providing a patient with information about autonomic bodily functions so that 
they may control said autonomic function. In the case of ADHD, neurofeedback focuses 
on reinforcing the behaviors and sensations associated with attentiveness. Currently 
however, neurofeedback systems are large and require a patient to travel to a clinic. 
Furthermore, the current offering of portable neuro/biofeedback devices do not have the 
technological capabilities to provide effective neurofeedback therapy. Current wearable 
tech devices – such as the Apple Watch and Samsung Gear – possess the technological 
capabilities to measure important bodily functions, and provide appropriate biofeedback 
therapy while remaining discrete and most importantly, portable.  
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Introduction 
Attention deficit hyperactivity disorder (ADHD) is a psychopathology commonly 
characterized by general inattentiveness and/or a lack of impulse control resulting in 
hyperactive tendencies (Barkley, 2015). Associated with symptoms like daydreaming, 
forgetting, fidgeting, and squirming, ADHD can greatly interfere with a child’s learning 
as well as an adult’s productivity in the workplace. These behaviors have serious 
economic consequences: ADHD is estimated to cost the United States roughly $266 
billion every year, 70% of which can be accounted towards loss of income and loss of 
work productivity for adults with ADHD (Doshi, 2012). 
In the United States, 11% of children ages 4 – 17 and 4.4% of adults have been 
diagnosed with ADHD (Pastor, 2015). These numbers have been steadily increasing 
since the 1970s, due in part to changes in diagnostic criteria and to an increased 
availability and acceptance of treatment through medication (Barkley, 2010). Of the 
aforementioned $266 billion cost associated with ADHD, 10% arises from special 
services ranging from educational accommodations to visits to the physician, whereas 
20% goes towards paying for medication (Doshi, 2012).  
The costs of medication and associated services to treat ADHD can be particularly 
significant in the United States, due to the expectation that patients will shoulder the costs 
of health care. According to Doshi (2012), the average American is estimated to spend 
$1,105 out of pocket on pharmaceuticals and medical goods. This cost represents over 
155% more than the combined average of all other nations in the data group. For ADHD, 
the breakdown per year on an individual level is estimated to include education costs of 
roughly $3,000 per person in a family, and medication and healthcare costs of roughly 
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$2,500 per person in a family. My personal experience as an individual with ADHD is 
illustrative of how quickly costs can increase. Every three months, I must pay $650 for a 
bottle of 90 pills. Every time I am prescribed these pills, I must go into my physician’s 
office for a check-up, bringing the real cost of my prescription up to $1,250. In total per 
year, I spend $5000 on medication alone.  
However, as the number of ADHD diagnoses continues to increase, concerns 
about the over-prescription of ADHD medication have been rising (National Institute on 
Drug Abuse, 2016). Typical medications for ADHD are stimulants that act on 
neurotransmitters in the central nervous system. Along with their high economic costs, 
the effects of prolonged use of these substances is unclear, especially for individuals with 
less severe symptoms and/or ongoing neurodevelopment (National Institute on Drug 
Abuse, 2016). For this reason, the American Psychological Association (APA) and 
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) have 
identified a general desire and potential need to avoid prescribing drugs, especially to 
younger children. Together, the two organizations have conducted a series of studies 
identifying effective treatments for ADHD. 
According to research by these organizations, cognitive behavioral therapy (CBT) 
is an effective alternative to medication in both individual and group settings (Barkley, 
2010). However, the effectiveness of CBT is potentially limited in practice by the need 
for ongoing interactions with a therapist. Compared to the convenience of a pill that can 
be consumed anywhere at any time, maintaining a schedule of visits to the therapist may 
be a challenge, especially for individuals with attentional difficulties. 
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What is needed then is a method of providing the benefits and lasting effects of 
therapy, with the convenience of taking medication. Biofeedback – and more specifically 
neurofeedback – may provide the solution. Biofeedback is the process of measuring a 
subject’s physiological processes, and visualizing the measurements so that the subject is 
aware of the physiological processes. Neurofeedback is a similar process involving 
neurological signals and processes instead of physiological signals and processes. 
Biofeedback and neurofeedback are relatively new fields having emerged in the last half 
century but are already used extensively to treat a variety of ailments both physical and 
psychological.  
There are a few drawbacks to biofeedback and neurofeedback treatments; the 
biggest being transportability of treatment. To accurately measure and analyze brain 
signals, a large headset attached to a powerful desktop computer must be used, limiting 
the transportability of the system. Furthermore, because data is only collected when a 
patient is using a neurofeedback device, they must go to the clinician’s office for repeated 
sessions in order to collect sufficient amounts of data. However, a there may now be a 
solution.  
In the past 5 years, the consumer tech market has witnessed an explosion of 
“wearable tech”. Wearable tech is the term used to refer to any portable electronic device 
that is worn on the body such as a watch or glasses. These devices come with a variety of 
sensors built in with the purpose of measuring bodily functions including heart rate, 
blood oxygen levels, activity levels (steps taken, minutes spent exercising, etc.), and 
sleep patterns/quality. Currently, wearable tech is used to promote consumer health and a 
healthier life style, but the sensors and technology employed is underutilized.  
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This poses the question: can wearable tech devices be used as a biofeedback 
device for a psychological disorder such as ADHD?  The purpose of this thesis is to 
critically evaluate the data regarding biofeedback treatments and compare it to 
conventional treatments. If biofeedback and neurofeedback are both found to be effective 
treatments, then a proposal on how to employ wearable tech for the treatment of ADHD 
will be given.  
 
Biofeedback  
Biofeedback is the process of measuring a subject’s physiological processes, and 
visualizing the measurements so that the subject is aware of the physiological processes 
(Durand, Barlow, 2009). Biofeedback relies on physiological recording techniques that 
are typically electrical in nature: electromyography, electroencephalography, and 
electrocardiography. These methods were originally developed in a clinical setting and 
are used to measure various physiological phenomena within the body.  
Electromyography (EMG) is used to record the electrical activity produced by 
skeletal muscles (Tassinary, 2007). This is achieved by measuring the overall electric 
potential generated by cell muscles which, is measurable through a subject’s skin. 
Various muscular ailments are treated today using EMG biofeedback. One such ailment 
is Spastic Pelvic Floor Syndrome (SPFS). Spastic pelvic floor syndrome (SPFS) is a 
functional disorder of the pelvic floor muscle wherein during straining, the muscle 
contracts instead of relaxes, causing a functional rectal outlet obstruction (Dickinson, 
2006). Prior to EMG biofeedback, SPFS was commonly treated with laxatives and water 
enemas. Repeated use of such devices can leave lasting damage internally. The key 
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feature of the treatment is that a patient relearns normal, autonomous muscle functioning 
(Barnett, 2014).  
When a subject’s floor muscle is straining, their EMG measurements read 70+ 
microvolts; conversely, when a subject’s floor muscle is relaxed, their EMG 
measurements read >20 microvolts. While observing his/her EMG measurements in real 
time, a patient focuses on the sensation of his/her contracting muscles. Then, the patient 
must think about lowering the EMG levels, and focus on the muscle sensation that 
follows. As the patient focuses on the EMG read out, his/her muscles will contract or 
uncontract accordingly. The EMG read out allows the patient to observe, process, and 
control bodily signals that they were unable to process prior. In the case of SPFS, it is 
processing and controlling the signals between the brain and pelvic floor muscle. 
Furthermore, through repeated sessions, a patient can relearn control of a given muscle 
without the aid of an EMG readout, having relearned how to process his/her bodily 
signals.  
EMG biofeedback is only one of the three major biofeedback recording methods. 
Electrocardiography (EKG) and electroencephalography (EEG) are used in a similar 
manner when working with the heart and brain respectively. The major impact of 
biofeedback is that it is psychological in nature. Biofeedback does not require the use of 
medications or special medical procedures; all that is required are non-invasive sensors 
placed on the patient’s skin. Starting in 1958 – when Dr. George Mandler proved the 
existence of a link between psychological and physiological reactions – hundreds of 
studies have proven the efficacy of biofeedback in treating a variety of physiological and 
psychological pathologies (Thatcher, 2015).  
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In 1865, Claude Bernard proposed the theory of homeostasis. Homeostasis states 
the human body will actively regulate bodily functions to maintain a state of constant 
being. The theory stated that each bodily function was regulated and controlled by a 
biological mechanism known as a homeostat. Bernard proposed that if a person was able 
to control a homeostat, they would have voluntary control over the corresponding bodily 
function (Bernard, 1957). Twenty years later, Ivan Tarkhanov, a Russian physiologist 
most known for his discoveries in the heart and circulatory system, demonstrated that 
voluntary control of one’s heart rate was relatively easy through simple concentration on 
the sensation of the beating heart (Tarchanoff, 1885). At the time, the discovery remained 
little more than a scientific amusement.  
The next major step in the establishment of biofeedback as a legitimate field of 
study came in 1958. Austrian scientist George Mandler conducted an experiment 
regarding autonomic self-perception, the awareness of one’s automatic physiological 
responses; i.e. sweating when stressed, crying when sad, hyperventilating when scared. 
Mandler was specifically interested in the relationship between the severity of autonomic 
reactions to one’s awareness of autonomic reactions (Mandler, 1958). Using a self-
assessment questionnaire and an interview, Mandler found 14 subjects (Group A) with 
high autonomic reaction scores and 9 subjects (Group B) with low autonomic reaction 
scores. Subjects from both groups were then placed in high-anxiety situations – difficult 
paper exams, scary movies/images – while their autonomic reactivity was measured via 
heart rate, psychogalvanic response, respiration, face temperature, and blood pressure. 
Subjects were then asked to self-report their own perceived stress level as well as their 
own perceived autonomic response level. Mandler’s results showed there was a positive 
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correlation between a subject’s self-reported response levels and their observed response 
levels (Mandler, 1958). Furthermore, the results revealed that subjects with a high level 
of responsiveness almost always overestimated their stress levels while subjects with a 
low level of responsiveness almost always underestimated their stress levels. The results 
demonstrated two things. First, the results demonstrated a link between psychological and 
physiological reactions. Second, and more importantly, the results suggested that if a 
subject could control their autonomic responses, they could control their psychological 
responses. 
4 years later in 1962, Donald W. Shearn, an American scientist conducted an 
experiment to determine if a subject could control their heartrate. Shearn took 46 
undergraduate male volunteers and provided each subject with a heartrate monitor. Over 
the course of 20, 30 second trials, each subject was asked to attempt to raise their 
heartrate without the use of hyperventilation. If the subject didn’t successfully raise their 
heartrate they were given a mild shock. Results showed that with each session, the 
number of times a subject could raise their heartrate increased (Shearn, 1972). 
Furthermore, the results showed that if a subject was given less time before the shock, 
they were still able to adapt and rapidly increase their heartrate voluntarily. The results of 
this experiment demonstrated that it was possible to control one’s heartrate by simply 
watching a heartrate monitor. Furthermore, the results This was the first recorded use of 
modern biofeedback. 
Despite Shearn’s discovery, his experiment wouldn’t be peer-reviewed until a 
decade later in 1972 with the release of the ‘Handbook of Psychophysiology’. The peer 
review included a replication of Shearn’s experiment, conducted by Thomas McCanne 
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and Curt Sandman (Dawson, 2007). The experiment involved twelve healthy male 
volunteers from an undergraduate psychology class. Like Shearn’s study, each subject 
was presented with a heartrate monitor. McCanne and Sandman’s experiment focused on 
a few methodological concerns.  
The first method change was that each subject would be asked to both accelerate 
and decelerate their heart rate. McCanne and Sandman were interested in the possibility 
of different psychological mechanisms involved in learning how to accelerate and 
decelerate one’s heartrate. The second method change was that each subject would go 
spend a week conduction sessions instead of a few minutes total. Specifically, each 
subject would spend five consecutive days with 10, 30 second sessions each day. The 
purpose of this change was to determine if control of autonomic physiological functions 
could be learned. The results of the experiment revealed that not only indeed could a 
subject control an autonomous function such as their heart rate, it became clear that the 
subjects had learned how to accelerate and decelerate their heart rate by the end of the 
trial, having learned how to do so throughout the week of tests (Dawson, 2007). A 
demonstrated and proven ability to learn physiological and psychological self-control 
meant that psychological therapies could be used in lieu of drug-based therapies for 
physical ailments.  
In 1976, the Biofeedback Society of America was established – know known as 
The Association for Applied Psychophysiology and Biofeedback – with the goal, as 
stated by the AAPB, is to “promote a new understanding of biofeedback and advance the 
methods used in this practice.” Soon thereafter, the AAPB researcher John Basmajian 
published Biofeedback: Principles and Practice for Clinicians (Basmajian, 1979). The 
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purpose of Dr. Basmajian’s publication was to serve as a central source of knowledge 
regarding then-current biofeedback techniques. One particular field of interest was 
musculoskeletal manipulation of normally autonomous processes; a form of 
electromyographic biofeedback (EMG).  
As the medical community’s understanding and acceptance of biofeedback grew, 
the understanding and acceptance of neurofeedback grew as well. Neurofeedback, much 
like biofeedback, is the attempt to manipulate normally autonomous mental functions 
through the observation of physiological brain-wave readings. The primary area of 
treatment that neurofeedback is aimed at is psychopathologies. In 1994, the AAPB 
established a dedicated research group for brain-wave feedback as well as a dedicated 
research group for EMG feedback.  
That same year, the EMG group published an experiment focusing on the efficacy 
of biofeedback in regards to stress and pain management. The experiment – conducted by 
Dennis C. Turk, Hussein S. Zaki, and Thomas E. Rudy – involved 80 subjects suffering 
from temporomandibular joint dysfunction (TMD) (Turk, 2002). The 80 subjects were 
randomly assigned to one of three groups. The first group (Group A) would receive 
traditional oral painkillers and would be asked to rate their pain levels following 
treatment. The second group (Group B) would receive a biofeedback-based stress/pain 
management treatment. Group B was shown a collection of biofeedback readings 
consisting of skin conductance, heart rate, blood pressure, and EMG readings of the jaw 
muscle. Subjects in Group B would be asked to focus on lowering the biofeedback 
readings while remembering the sensation of the lower pain levels. The third group 
(Group C) was a control group and didn’t receive any treatment. The results indicated 
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that subjects in Group A experienced higher levels of relief than subjects in Group B 
following treatment. This was partially to be expected given that TMD is the 
inflammation of the jaw joint. Following the initial experiment, a 6-month follow up was 
conducted to determine how the subjects’ pain management has progressed. Subjects in 
Group A severely relapsed in pain management, a majority of the subjects still relying on 
pain medication. Subjects in Group B, however, showed a marked improvement in their 
pain management and comfort. Furthermore, a repeat experiment was conducted where 
30 subjects were given both oral painkillers and biofeedback-based treatment. This group 
showed better improvement than either Group A or Group B, using pain killers for early 
relief and transitioning to psychological methods of pain management (Turk, 2002). The 
results of this experiment were important because it was one of the first times that 
biofeedback had been used to manage pain rather than a specific muscle function. This 
was one of the first large steps towards the validation of meditation and thought therapy 
as a useful medical tool for patient pain management.  
 
ADHD & Neurofeedback  
ADHD is a psychopathology commonly characterized by general inattentiveness 
and/or a lack of impulse control resulting in hyperactive tendencies. The Diagnostic and 
Statistical Manual, 5th Edition (DSM-5) categorizes the symptoms of ADHD into two 
categories: inattention, and hyperactivity and impulsivity. There are three presentations of 
ADHD that can occur based on the symptoms present in an individual; they are as 
follows: ADHD-Predominantly Inattentive, ADHD Predominantly Hyperactive-
Impulsive, and ADHD Combined. The symptoms associated with ADHD can interfere 
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with a child’s learning as well as an adult’s productivity in the workplace. For example, 
an individual with ADHD-Predominantly Inattentive (such as this author), will often have 
trouble holding attention on tasks, won’t seem to listen when spoken to directly, and 
often loses things necessary for tasks and activities such as eyeglasses or cell phone. In 
contrast, individuals with ADHD Predominantly Hyperactive-Impulsive will often fidget 
and squirm when seated, have trouble staying seated for extended periods of time, and 
talk excessively or out of turn. In order for an individual to be diagnosed with ADHD, he 
or she must not only display 6 or more symptoms, but there must also be clear evidence 
that the symptoms present interfere with, or reduce the quality of, social, school, or work 
functioning. The symptoms present must also be deemed inappropriate for the age or 
developmental level of the individual in question (American Psychiatric Association, 
2013).  
The exact cause of ADHD is unknown, but there are several risk factors that can 
contribute to the development of ADHD. If a blood relative, such as a parent or sibling, 
has ADHD or similar psychopathology, an individual will be more likely to develop 
ADHD. Maternal drug or alcohol abuse as well as premature birth are both identified risk 
factors in the development of ADHD. ADHD shares a co-morbidity with several other 
psychopathologies including depression, bipolar disorder, Tourette Syndrome, and 
general anxiety disorders (Kessler, 2006). Each of the listed psychopathologies – 
including ADHD – can be characterized by a chemical imbalance in the brain; more 
specifically, an imbalance of key neurotransmitters (American Psychiatric Association, 
2013). 
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At the neural level, individuals with ADHD are often described as being in an un-
aroused state (Bakhshayesh, 2010). Critically, the ADHD brain shows measurably lower 
levels of one of two specific neurotransmitters: dopamine or norepinephrine. ADHD 
Hyperactive-Impulsive is associated with lower levels of dopamine, which is involved in 
the regulation of reward-motivated behavior, emotional responses, and motor control. 
Consistent with the role of dopamine in motor control, symptoms associated with ADHD 
Hyperactive-Impulsive include constant fidgeting or vocal outbursts (Daly, 2015). Due to 
dopamine’s role in reward-motivated behavior, symptoms also include general 
impatience and a desire to complete a task using minimal effort, often at the cost of 
quality (Barkley, 2015). Lower dopamine levels associated with ADHD Hyperactive-
Impulsive can also be observed as emotional immaturity. Individuals with ADHD 
Hyperactive-Impulsive are often characterized as having difficulty maintaining 
relationships both intimate and not (Goldstein, 2000). 
ADHD Inattentive is marked by reductions in norepinephrine levels. 
Norepinephrine is responsible for promoting vigilance, formation and retrieval of 
memory, and focusing attention. Consistent with norepinephrine’s role in vigilance, 
symptoms associated with ADHD Inattentive include being easily distracted and 
difficulty following through on instructions (Prevatt, 2015). Due to norepinephrine’s role 
in memory formation and retrieval, symptoms also include difficulty remembering items 
in a short amount of time as well as difficulty remembering items without an external aid 
in the form of notes (Prevatt, 2015).  
In all three subtypes of ADHD, the imbalance of neurotransmitters means that 
neuronal connections are weaker. The weaker connection – and imbalance of 
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neurotransmitters – is attributed to overactive neurotransmitter transporters. 
Neurotransmitter transporters are proteins found in the cell membrane of a neuron. The 
transporters are responsible for moving neurotransmitters across the cell membrane to 
change the neuron’s cell potential and in turn trigger an electrical signal: the neuron firing 
(American Psychological Association, 2013). The transporters in an individual without 
ADHD only move neurotransmitters across the cell membrane when necessary, building 
up a ready supply of neurotransmitters ensuring that the action potential can be quickly 
triggered. In an individual with ADHD, the transporters are overactive. An overactive 
transporter moves neurotransmitters across the cell membrane too frequently which, in 
turn deprives the neuron of a neurotransmitter reserve. Specifically, an overactive 
transporter will move neurotransmitters outside of the cell, inhibiting the reuptake of 
neurotransmitters (Pedraza, 2015). By depriving the neuron of an available supply of 
neurotransmitters, more time is required to trigger the action potential, slowing down the 
entire signal chain.  
This delayed neural firing can manifest itself in different behaviors—again, 
depending on the ADHD subtype. In the case of ADHD Hyperactive-Impulsive, a lack of 
dopamine and slower firing neurons can appear in a patient, for example, as a delayed 
impulse control or inability to wait their turn. A lack of norepinephrine and slower firing 
neurons in ADHD Inattentive can appear in a patient, for example, as an inability to 
quickly memorize information or propensity to misplace items (Pedraza, 2015).  
There are two commonly accepted methods of treatment for ADHD. One is to 
increase dopamine and norepinephrine levels in the brain to compensate for the 
overactive transporters. The second is to inhibit the transporters so fewer 
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neurotransmitters are moving across the cell membrane. Currently, there are two classes 
of medications available: stimulants and non-stimulants (American Psychological 
Association, 2013). Stimulants and non-stimulants are used to treat both ADHD 
Hyperactive Impulsive and ADHD Inattentive; whether simulants or non-stimulants are 
used is dictated by the treatment method used. Both types of medications allow a 
patient’s neurons to build up a neurotransmitter reserve, ready to be moved across the cell 
membrane when necessary (American Psychological Association, 2013). The availability 
of neurotransmitter reserves is reflected in reduced neurotransmitter  
Standard medications provide a subject’s brain with the means to produce the 
needed neurotransmitters which, in turn allows the neurons to fire more rapidly due to the 
reduced time required to build up neurotransmitters. By increasing the rate of neuronal 
communication, these drugs allow the individual to function “normally”; i.e. no longer 
engage in or display disruptive symptoms. However, neuronal communication is 
enhanced for only as long as the medications last; once the medication has run its course, 
the subject’s brain is no longer able to facilitate improved neuronal connections. 
Furthermore, as with any drug, tolerance will build up over time, requiring higher and 
higher doses for the medications to remain effective. To combat the need for higher 
doses, subjects are often taught certain psychotherapies or coping methods that naturally 
facilitate improved neuron communication; methods can include frequent exercise/time 
outside, avoiding unhealthy foods, and taking frequent notes. Patients might also engage 
in cognitive behavioral therapy (CBT) which trains a patient to identify problematic 
behaviors and how to manage said behaviors (Pedraza, 2015).  
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Behavioral intervention – or cognitive behavioral therapy (CBT) – helps patients 
recognize patterns or problem behavior so that they better manage the identified patterns 
(American Psychiatric Association, 2013). Furthermore, parents and teachers will be 
given strategies to cope with disruptive behavior as well as address problematic 
behavioral habits at home and at school. Per a series of studies conducted by CHADD 
and the APA, CBT was found to be effective in both an individual and group setting. In 
all but one of the studies, CBT yielded significantly improved behavioral patterns and 
habits in the subjects (Pedraza, 2015). When CBT was used to help subjects improve 
their behavioral habits and patterns, subjects felt that they were being helped and that 
their “normalcy” was being reaffirmed (Gevensleben, 2012). CBT is a broad term and 
can be achieved through a variety of settings. A therapist or “life coach” can be 
considered a form of CBT as well as meditation and/or yoga.  
But why does CBT work? CBT works because the subject is made aware of their 
behavioral habits. The subject is effectively trained to realize when he/she is engaging in 
a behavioral habit and what must be done in such an event. What makes CBT truly 
effective however, is the fact that there is a trained professional with the subject making 
them aware of their own habits. Once the subject is on their own, they are less likely to be 
aware of their behaviors and furthermore will be more likely to regress in their behavioral 
management techniques. Much like medication, the subject is still reliant on treatment to 
aid in their behavioral management (Gevensleben, 2012). Unlike a pill, therapists cannot 
travel with the subject to aid in correcting behavioral habits. If a therapist cannot travel 
with the subject, feedback needs to be provided to the subject via another method. 
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Without psychotherapy or medications (or a combination of both), a subject is unable to 
facilitate improved neuronal communication.   
The aim of neurofeedback is to give subjects the ability to facilitate improved 
neuronal communication without the aid of medications or psychotherapy (Lofthouse, 
2011). Neurofeedback relies on the principle that a subject’s arousal (attentiveness) is 
dependent on the pattern of neural oscillations with the brain. Neural oscillation is 
repetitive neural activity within the brain. A single neuron repeatedly activating is said to 
be oscillating or displaying oscillatory activity. On a single-neuron scale, the oscillations 
appear as oscillations in the membrane potential. At the level of neural ensembles – 
groups of neurons activating in synchrony – the synchronized oscillations are measurable 
through the scalp using an electroencephalogram (EEG) and appear as signal frequencies, 
or brain waves.  
There are four well-studied brain wave levels: delta, theta, alpha, beta. Delta 
waves range from 0.5 to 3.0 Hz and are present only when a subject is engaged in deep 
sleep. Theta waves range from 3.0 to 8.0 Hz and are present during light sleep and when 
a subject is awake but inattentive. Alpha waves range from 8.0 to 13 Hz and are present 
during any waking moment, and will disappear during moments of attentiveness. Beta 
waves range from 13 to 22 Hz and are present when a subject is alert, attentive, or 
engaged in various high level mental thoughts (Lofthouse, 2011).  
As in biofeedback, a representation of the measured brain signals is shown to the 
subject for the purpose of teaching the subject to learn to regulate their brain activity. The 
brain signal representation often takes the form of a video game (Monastra, 2008). When 
a subject’s brain wave activity indicates arousal and attentiveness – meaning their brain is 
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producing beta waves – the subject is given positive feedback. With this system, subjects 
are not only trained to regulate their brain activity, but are also trained to be more 
perceptive of how an attentive brain feels (Schummer, 2013). 
However, it remains an open question how well neurofeedback works. Various 
clinical studies have been conducted to determine the efficacy of neurofeedback. In any 
study regarding ADHD severity, a battery of tests is used. The Test of Variables 
Attention (TOVA) is a neuropsychological assessment that measures a subject’s level of 
attentiveness while simultaneously screening for ADHD. The test is typically presented 
as a simple and repetitive game on a computer. The test is meant to measure a subject’s 
response to auditory and visual cues. A high TOVA score is indicative of an alert and 
attentive subject while a low TOVA score is indicative of a non-attentive subject 
(American Psychiatric Association, 2013).  
Another test used to diagnose ADHD – among a variety of learning disabilities – 
is the Wechsler Intelligence Scale for Children (WISC). The WISC measures verbal 
comprehension, visual spatial skills, fluid reasoning, working memory, and processing 
speeds. The test is presented as a combination of verbal exams and paper exams. Along 
with the WISC, there is the Wechsler Adult Intelligence Scale (WAIS) (American 
Psychiatric Association, 2013). Like the WISC, the WAIS is a diagnostic tool used to 
measure intellect and cognitive ability in adults. The WAIS measures the same variables 
as the WISC, but uses different prompts that are more suited for adults and older 
adolescents. 
Another commonly used diagnostic tool is the D2 Test of Attention. The D2 Test 
of Attention is a neuropsychological test meant to measure selective and sustained 
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attention of a subject. On a piece of paper, a subject must be able to find and highlight 
specific letters – usually the letter “d”. The object of interest is placed among distractor 
objects that have a similar shape – in the case of the letter “d”, each letter could be 
surrounded with “p” or “q” (American Psychiatric Association, 2013).  
All the tests discussed have been translated and are used world-wide. Due to the 
tests’ common use in diagnosing ADHD, studies involving ADHD and behavioral issues 
will use these three tests along with peer interviews to measure the severity or change in 
ADHD for any given subject (American Psychiatric Association, 2013).  
The results pertaining to ADHD and neurofeedback have all been generally 
positive. In a study looking at the efficacy of EEG neurofeedback in training various 
ADHD coping strategies, children and adolescents (ages 8-19) participated in a 3-month 
long program of intensive neurofeedback training where reward was dependent on 
maintaining high beta-wave levels while avoiding theta waves (Lubar et al., 1995). 
Following the 3-month program, almost all subjects demonstrated improved TOVA 
scores, behavioral ratings, and better WISC-R performance. More importantly, these 
improvements were comparable to those of a subject on traditional medications (Lubar et 
al., 1995).  
A similar study was conducted to compare the efficacy of EEG neurofeedback to 
the efficacy of traditional medications; in this case, methylphenidate. 22 children (ages 8-
12) participated in a 3-month long program of intensive neurofeedback training while 12 
children (ages 8-12) were given methylphenidate over the same 3-month period (Fuchs et 
al., 2003). Following the 3-month program, both groups demonstrated improved d2 
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Attention Endurance Test scores and behavioral ratings from parents and teachers. These 
results demonstrated that EEG neurofeedback was as effective as medications.  
 In one study, 100 children and teens with ADHD (ages 6-19) were given a variety 
of treatments, including medication, school consultation, and parent counseling 
(Monastra, 2002). Half of the children received this regimen while the other half received 
this regimen along with EEG neurofeedback training. After a year of treatment, both 
groups stopped taking the medication and measurements were taken a week later. TOVA 
and behavior scores for children who received neurofeedback were found to be in the 
“normal” range, or not indicative of ADHD. The scores for children who did not receive 
biofeedback were in the “clinical” range, or indicative of ADHD. Furthermore, children 
who did not receive neurofeedback started to exhibit ADHD symptoms just a week after 
not taking medication and sooner in some cases (Monastra, 2002). This study 
demonstrated that neurofeedback is not only an alternative treatment, but is an additive 
treatment in the presence of traditional treatments.   
Despite its demonstrated efficacy and success in treating ADHD, neurofeedback 
still has flaws, some more glaring than others. While neurofeedback eliminates the need 
for medication, a subject won’t necessarily pay any less than before. On average, a single 
neurofeedback session costs anywhere from $50 to $125 and in order for neurofeedback 
to be effective, a subject must undergo 30 to 40 sessions each lasting 2 hours; these are 
all the costs AFTER a subject has seen a psychiatrist and physician (Gevensleben, 2012). 
Furthermore, due to the novel nature of neurofeedback, many insurance companies view 
neurofeedback as experimental, and will not cover the costs. The bulk of the cost for 
neurofeedback treatment is in the time spent at the clinic. Whilst small, portable 
20 
BIOFEEDBACK & ADHD 
consumer brain-reading devices have been on the market for almost a decade now, these 
devices have been little more than toys, incapable of getting the accurate measurements 
required for neurofeedback treatment. The devices required for neurofeedback treatment 
cost upwards of $25,000.  
What is needed then is a portable device capable of making accurate, reliable, and 
usable measurements. More importantly, a device that is discrete is required. The success 
of non-medication-based treatments of ADHD, such as CBT, hinge on the subject feeling 
“normal” despite their disorder. Brain-reading devices, both consumer and non-consumer 
are large and ungainly by nature; even the latest consumer device, the MUSE, is a wide 
headband that covers a large part of the user’s forehead and sides of their head. A subject 
feeling such a device will not appear as normal and thus most likely will not feel normal.  
 
Proposed Device  
As described above, the development of an effective biofeedback device for 
ADHD faces key challenges, including portability, accuracy, and discretion. In this 
section, I will review existing devices that have been developed to address these criteria, 
as well as assessing the technological capabilities of consumer wearable tech and how 
consumer tech could be used as a clinical biofeedback device. Based on this analysis, I 
conclude that no currently available device fully meets the needs of the ADHD 
population. Instead, I propose that rather than developing a bespoke device, current 
consumer wearable tech be repurposed to provide clinical biofeedback through means of 
a bespoke app capable to using the technology found in wearable tech.  
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In cooperation with several pharmaceutical companies – including Shire, the 
makers of Adderall – the APA has designed and validated several biofeedback-based 
CBT computer programs. While using the CBT program, the subject’s neurological 
processes are recorded using an EEG cap so that the program may provide guidance 
accordingly. Much as a therapist would, these programs provide a subject with self-
regulation techniques and exercises. Data suggest that CBT computer programs are 
successful in treating ADHD (Janessen, 2015). This success stems in part from the fact 
that the programming allows the recording device to act on the recorded data. However, 
like a therapist, computers capable of running CBT programs are restricted in movement 
and typically only exist on desktop systems. Although devices for neurological 
monitoring are themselves portable enough for a subject to use on a regular basis and 
cost little more than a single drug prescription, these monitoring devices do little else 
than record data. Even the most advanced portable recorder produced by the leading 
biofeedback device manufacturer (Current Technology Inc., Minneapolis, MN) lacks 
programmable logic, the ability to run any sort of on-board data analytics. Therefore, 
what is needed is a data recording device capable of data analytics—a portable computer. 
To address this issue, several biomedical companies have released apps and proprietary 
devices that together can perform a wide variety of tasks. However, on their own, each 
device is highly specialized, providing information pertinent to one or few  
Thanks to advancements in modern computing, though, most of the population 
has access to a portable computer, in the form of a smartphone. Smartphones are 
incredibly powerful devices – the iPhone is more powerful than the computer on Apollo 
11 – that can be connected to any number of devices. These devices include headsets, 
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cars, and most importantly, bio recording devices. As smartphones continue to advance, a 
new market has emerged which might provide a universal biofeedback device: wearable 
tech. 
Wearable tech was introduced to the consumer market with the release of the Fit 
Bit in 2007. The Fit Bit is marketed as an activity motion tracker capable of counting a 
subject’s steps, measuring their heart rate, measuring their blood-oxygen levels, sleep 
schedule, and exercises performed (FitBit, 2016). Furthermore, the device acts as a 
communication device for the phone, allowing a user to talk on the phone and reply to 
texts without needing to directly access the smartphone. The Fit Bit device itself is worn 
on the subject’s wrist and is smaller and lighter than most watches. Since the introduction 
of the original Fit Bit, the wearable tech market has grown to a nearly $14 billion 
industry with 60 million devices being sold each year (Statista, 2016). Major consumer 
electronics companies including Apple and Samsung have entered the market with well-
known devices such as the Apple Watch and Samsung Gear. Thus, wearable tech devices 
have the benefit of already being a popular technology, eliminating the need to create 
bespoke sensors and devices.  
However, despite the popularity of wearable tech, their location on the body (e.g., 
wrist) limits their capabilities to motion tracking and blood flow monitoring. Although 
head-mounted technologies such as virtual reality are receiving new attention (Statista, 
2016), to date no neurological recording device has been designed for discreet, portable 
day-to-day wear. This means that for a wearable-tech device to be successful, it must be 
possible to monitor a psychological disorder using these types of physiological 
measurements. 
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In the case of ADHD, existing technologies have instead focused on directing the 
user’s attention towards specific reminders and tasks. Currently, there are a number of 
wearable devices on the market that are designed to aid in directing a user’s focus, 
including the WatchMinder and T.Jacket. The WatchMinder (WatchMinder, 2016) is a 
small watch-life device that allows a user to create discreet cues throughout the day that 
remind them to perform specific tasks. These tasks are determined by the user, but 
examples include a child receiving notifications of when to take medications, or an adult 
being reminded of an upcoming meeting at work. Similar functionality is provided by 
other wristband devices such as the Re-vibe and Sqord (FokusLabs, 2016) (Sqord, 2016).  
Another similar device is the T.Jacket. Similar to the WatchMinder, the T.Jacket 
provides discrete reminders to the user to perform certain tasks. However, unlike the 
WatchMinder, the T.Jacket (as the name implies) is a jacket-like piece of clothing that the 
user wears. The reminders are delivered via pressure applied by the jacket (imagine a 
hug) and can be remotely delivered by a parent or caretaker if necessary (TWare, 2016).  
Despite their prevalence on the market, these devices suffer from major flaws, 
including requiring user input, being subject to habituation, and lacking awareness of the 
user’s physiological state. First, the current offering of devices requires that the user set 
up reminders, which limits the functionality to dealing with events or tasks that are 
already scheduled. Furthermore, because most of these devices don’t have a screen, they 
rely on the user to remember what the task in question is. When dealing with 
psychopathologies that affect memory, such as ADHD, this can lead to obvious 
problems. Worse, most current smartphones already come with reminder systems that 
have equal or greater capability. For example, both the iPhone and Samsung Galaxy can 
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deliver reminders based on a variety of conditions beyond time – location, whom the user 
is talking to, current activities – as well as delivering reminders just as discreetly. 
 This style of schedule or task reminder also suffers from habituation. As with 
medications, it is possible for users to build a “tolerance” to the reminders, especially if 
they are time-based (Thatcher, 2015). Over time, the user will learn to anticipate the 
reminders, and depending on the task, could begin to intentionally ignore the reminder. 
This is especially the case when children must take medications at specific times 
(Schummer, 2013). Furthermore, none of the current devices can deliver “context 
dependent” reminders. A context dependent event is an event that will only occur when 
certain criteria are met. In terms of reminders and scheduling, a context dependent 
reminder is a reminder that will only appear when necessary. For example, a child that 
needs to take medications at a specific time while at school won’t want to receive 
reminders while on vacation or during the weekend when taking medications isn’t 
necessary.  
 It is important to note that reminders are not detrimental or useless to those with 
ADHD; quite the opposite in fact (Salomone, 2012). However, reminders do not serve a 
therapeutic purpose. Reminders are simply another tool for those ADHD to rely on, and 
do not aid in the memory formation or recall necessary to remember tasks and 
instructions. What is required is a therapeutic device that responds not simply to time or 
location, but also responds to the current task at hand and most importantly, the current 
focus level of the user. As stated earlier, the device I am proposing wouldn’t be able to 
measure brain activity; it must rely on physiological measurements representative of the 
user’s attentiveness.  
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 Current wearable tech can detect what type of motion or exercise a user is 
performing based on the measured wrist motions and accelerations. Furthermore, 
wearable tech – using the same methods – can determine a user’s body position or stance 
and provide feedback accordingly. It stands to reason that this technology could be 
repurposed to detect when a user is attentive or inattentive. Studies conducted in the last 
year suggest that there is indeed a body position associated with attentiveness and a body 
position associated with inattentiveness; most importantly, the body positions are 
measurably different from each other. However, the specific details of the body positions 
are still debated. 
 One study involving 110 adolescents (13 – 17 years old) with ADHD Combined 
measured each subject’s body position and movements during times that required focus 
(Cheung et al., 2016). Data was collected over the course of six years. The study revealed 
that subjects who were focused would almost always engage in a “preparation-vigilance 
measure”. A preparation-vigilance measure, per the study, was a biomarker that was 
closely correlated with higher levels of attention. In this case, the preparation-vigilance 
process varied from subject to subject, but followed a similar pattern: prior to focusing, 
the subject would engage in a pattern of deep breathing, shaking out their arms, or a 
closing their eyes for a moment. Subjects who didn’t engage in a similar activity almost 
always exhibited lower levels of attentiveness and awareness. Results also suggested that 
subjects who continued to engage in preparation-vigilance processes were more likely to 
experience a remission in their ADHD and associated symptoms (Cheung et al., 2016).  
 Deep breathing and shaking of the arms can both be detected using current market 
technology. The breathing could be detected via a sudden change in heart rate and blood 
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oxygen levels using a heart rate monitor, whereas shaking of the arms could be detected 
via gyroscopes and accelerometers. Both of these technologies are already found in 
wearable tech products. By measuring and identifying these physiological markers of 
focus, a context dependent device could be developed that knows when it is time to 
focus, and it is not. However, this is only useful if the device is also capable of keeping a 
user focused; in other words, knows when the user loses focus.  
 Evidence from research suggests that in patients with ADHD, decreased motion is 
associated with worse executive function. A study involving 29 children with ADHD 
Hyperactive Impulsive and 23 children without ADHD (8 – 12 years old) compared 
subjects’ activity level to their working memory performance (Sarver et al., 2015). Each 
subject performed four different working memory exercises while their physical activity 
levels were monitored and recorded. Results revealed that working memory performance 
was measurably improved during high rates of physical activity in subjects with ADHD. 
Conversely, subjects without ADHD had higher working memory performance during 
lower rates of physical activity. Further research must be (and is currently being) 
conducted to determine why those ADHD rely on physical motion; but this study 
provided more evidence for physiological detection of focus. Similar to how they detect 
exercises, wearable tech could monitor the physical motions associated with working 
memory functions, and detect when a user’s working memory is underperforming.  
 Another measurable physiological factor associated with ADHD is sleep 
disruption. Studies suggest that the severity of ADHD symptoms are determined by how 
well rested a subject is (Gaultney, 2005). For example, one study recorded the sleep 
patterns of 283 subjects with ADHD (birth – 18+ years old) and compared the sleep 
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patterns to reported behaviors. The results suggested a strong correlation between poor 
sleep and an increase in negative behaviors (impulsive acts, resistance to authority, lower 
cognitive performance). After controlling for age, the correlation was still present. This 
study suggests that sleep can determine how focused or not focused a subject will be 
throughout the day. This is information that can be used by a context-aware device. 
Current wearable tech devices – and smartphones in general – have built in sleep 
measuring capabilities that detect a user’s movement, body position, and noise levels 
during sleep.  
Based on these measurements, a device can determine approximately which stage 
of sleep a user is in at any given moment. This ability to determine a user’s quality of 
sleep lends itself towards creating a context-aware device. For example, if the device has 
information that a user with ADHD slept poorly in the previous night, it could be 
programmed to provide more frequent feedback or monitoring to compensate for poor 
sleep.  
Above all else, however, wearable tech is discrete. Unlike neurofeedback devices 
such as the MUSE, wearable tech is no less discrete than a wrist watch or pair of glasses. 
The size and convenience of wearable tech have been the primary drivers of the 
popularity of wearable tech. This rise in popularity means that as time goes on, everyone 
– regardless of mental health – will have a wearable device of some form, further 
decreasing the stigma that might have existed from wearing biofeedback-specific devices.  
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Conclusion 
 Using wearable tech, it is possible to create a biofeedback device capable of 
providing real time feedback therapy for a user with ADHD. This would most likely be 
achieved through the development of a bespoke algorithm – or app – that measures and 
responds to the various biological readings provided by the device. Some companies have 
already begun to develop apps that provide neurofeedback. One such example is FOQUS 
(Foqus Labs, 2016).  
 FOQUS is an experimental app that aims to address the mental health issues of 
ADHD. FOQUS does so by providing a patient with text based alerts, time management 
techniques, and guided meditation. Initial testing of the app revealed that the app was 
successful in reducing users’ anxiety as well as improving their overall organization 
skills. However, FOQUS is still not a true biofeedback device. The next step in 
development would be to develop an algorithm that responds in real time to physical 
cues. FOQUS is still currently time based, and runs on a predetermined schedule. For 
example, rather than having a pre-set meditation period, the app would measure heart rate 
and movement, and if the user’s heart rate or movement is beyond normal parameters, the 
app would prompt the user to take a break or meditate. Similarly, if the app were able to 
detect overly long periods of stillness, it might prompt the user with a reminder.  
 In conclusion, the technology to develop a biofeedback device for ADHD is 
already on the market – and will only continue to improve. However, the efficacy of 
biofeedback in treating ADHD will only be as great as the applications developed for 
consumer tech. As wearable tech continues to improve, more and more apps will be 
released, ushering in a new area of affordable, long lasting, and personalized medicine.  
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